Live Breaking News & Updates on Exhibit Robust Opportunities

Stay updated with breaking news from Exhibit robust opportunities. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Worldwide CNS Therapeutics Industry to 2025 - Awareness Campaigns Launched by Pharma Companies to Benefit the Market


Share this article
Share this article
ResearchAndMarkets.com s offering.
The global market for CNS Therapeutics is projected to reach US$137.7 billion by 2025, driven by the urgent need to address the unmet medical needs of neurological disorders. Diseases of the brain and mind range from epilepsy, stroke, migraine, Alzheimer`s, Parkinson`s, dementia, multiple sclerosis, brain injuries, neuroinfections, schizophrenia, psychosis and other mental disorders. With unmet needs continuing to persist, societal and healthcare burden continues to increase.
Stroke and infections such as meningitis and encephalitis continue to be the leading cause of disability worldwide, pushing up the cost of nursing care, hospice and bringing down quality of life. The unmet needs are evident in all phases of drug development i.e. identification of therapeutic targets; optimization of lead compounds; gaps in toxicity and pharmacokinetics studies; and slow resolution of ethical issues, amon ....

United States , United Kingdom , Effexor Venlafaxine , Epidiolex Cannabidiol , Purdue Pharma , Eli Lilly Emgality , Risperdal Consta , Eli Lilly , Invega Sustenna , Laura Wood , Age Group , Lack Of Evidence , A New Research Demonstrates Effectiveness Of Gluconate , Janssen Pharmaceuticals Inc , Astrazeneca Plc , Teva Pharmaceutical Industries Ltd , Merck Co Inc , Pfizer Inc , Pharma Companies , Abbvie Inc , Sunovion Pharmaceuticals Inc , Otsuka Pharmaceutical Co Ltd , Fabre Kramer Pharmaceuticals Inc , Alkermes Plc , Roche Ltd , Neurocrine Biosciences Inc ,